Records containing: Renal Medullary Carcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study results posted · 2026-10-28Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
-
CLINICAL_TRIALS study record update · 2026-04-24A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
-
CLINICAL_TRIALS study record update · 2026-04-15Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
-
CLINICAL_TRIALS study record update · 2025-11-04Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
-
CLINICAL_TRIALS study record update · 2025-09-09Activity of Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-03-11A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
-
CLINICAL_TRIALS study record update · 2024-08-26A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2024-03-22Tazemetostat Expanded Access Program for Adults With Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-12-20Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial